Profile summary
EsoCap AG is a privately funded joint stock company based in Basel, Switzerland. EsoCap has successfully developed a unique, highly sophisticated platform technology with multiple applications for local drug therapy in patients with severe oesophageal diseases. EsoCap's technology guarantees a significantly longer contact time of drugs (small molecules, peptides, biologics and encapsulated mRNA treatment principles) in the oesophagus, resulting in a safe and highly effective treatment outcome. The lead candidate ESO-101 has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE). EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study with ESO-101 in five countries, demonstrating the clinical applicability of the platform technology. EsoCap has a strong and diversified intellectual property position as well as a highly complementary team and development infrastructure.
Show moreRecent Activities
About Match SDG
SDG Goals
Stay connected
Subscribe to our monthly newsletter
